Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Ensysce Biosciences, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 9 | 12 | +3 |
| Shares | 396.4K | 167.7K | −228.7K (−57.7%) |
| Value | $714.0K | $231.1K | −$482.9K (−67.6%) |
New holders (5)
Institutions that held Ensysce Biosciences, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 19,113 | $26.2K | 0.00% |
| Geode Capital Management, LLC | 16,430 | $22.5K | 0.00% |
| Two Sigma Securities, LLC | 14,616 | $20.2K | 0.00% |
| UBS Group AG | 147 | $203 | 0.00% |
| Bank of America Corp | 59 | $81 | 0.00% |
Sold out (2)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Anson Funds Management LP | 36,261 | $65.3K |
| Gsa Capital Partners LLP | 17,547 | $32.0K |